Diplomat Pharmacy to Distribute Recently Approved PARP Inhibitor Zejula in the US

Diplomat Pharmacy to Distribute Recently Approved PARP Inhibitor Zejula in the US
Diplomat Pharmacy will be one of the companies distributing Zejula (niraparib), a recently approved treatment for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in the United States. Zejula is an oral, once-daily inhibitor of the proteins poly(ADP-ribose) polymerase (PARP) 1 and 2. It is the first of its class to receive approval by the U.S. Food and Drug Administration (FDA) as a maintenance therapy for women with these cancer types. A maintenance therapy aims to keep cancer at bay in patients who responded well to a primary cancer treatment. Use of Zejula does not require that patients carry mutations in the BRCA gene (a known cause of ovarian cancer) or other biomarker. "For women living with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, Zejula (niraparib) offers new hope as a promising treatment option," Paul Urick, Diplomat's president, said in a news release. The approval of Zejula was supported by positive results obtained in the NOVA clinical trial (NCT01847274). This Phase 3, double-blind, placebo-controlled, international study enrolled 553 ovarian cancer patients to test the drug’s effectiveness and safety. Results showed that treatment with Zejula significant
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *